RE:RE:RE:RE:Photodynamic Therapy Market to grow at a CAGR of 8.22% Good point Eoganacht & DJDawg....
One last thing...
Adstiladrin cost $260K.
Ruvidar(TLD-1433) cost $300K.
Adstiladrin seem to be the best deal financially.
Except for...
Adstiladrin $260K is for one year of treatment.
Adstiladrin as mentioned in DJDawg post has a CR(complete response) of 18% at 18 months(and
decreasing). Ruvidar(TLD-1433) is for one treatment, you go in the hospital, get the treatment and go home(hopefully cancer free).
As we speak Ruvidar(TLD-1433) has a CR of 33% at 15 months(and
increasing).
Note...
In the next TLD-1433 data update (end of Aug), the 450 days CR%(33%) will easily be around 34-36%CR(and
increasing), approximately 90-100% better than Keytruda & Adstiladrin at 18 months.
In short...Ruvidar(TLD-1433) $300K is the best deal for the money.
Eoganacht wrote: Just to add on to this - the FDA approved
Adstiladrin based on
CR rates of 51% at any time and 23% at 12 months. TLD1433 currently has
CR rates of 66% at any time and 33% at 15 months.
That
33% CR at 15 months will likely increase substantially by the end of the trial.
DJDawg wrote: It is the most recent approved therapy for NMIBC. Approved Dec 2022 but not available yet as it is very very difficult to make in large batches. Complex biologic agent. So far it is keytruda and adstiladrin. Keytruda's data is very poor and many wonder how/why it got approved.